title: Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
abstract: CD133 is one of the most commonly used markers of pancreatic cancer stem cells (CSCs), which are characterized by their ability for self-renewal and tumorigenicity. Although the expression of CD133 has been reported to correlate with poor prognosis of PDAC in most literatures, some controversies still exist. In this study, we aimed to investigate the correlation between CD133 expression and prognosis and clinicopathological features in PDAC. A search in the Medline, EMBASE and Chinese CNKI (China National Knowledge Infrastructure) database (up to 1 March 2015) was performed using the following keywords pancreatic cancer, CD133, AC133, prominin-1 etc. Data from eligible studies were extracted and included into meta-analysis using a random effects model. Outcomes included overall survival and various clinicopathological features. We performed a final analysis of 723 patients from 11 evaluable studies for prognostic value and 687 patients from 12 evaluable studies for clinicopathological features. Our study shows that the pooled hazard ratio (HR) of overexpression CD133 for overall survival in PDAC was 0.58 (95% confidence interval (CI): 0.49-0.67) by univariate analysis and 0.73 (95% CI: 0.52-1.03) by multivariate analysis. With respect to clinicopathological features, CD133 overexpression by immunohistochemistry (IHC) method was closely correlated with clinical TNM stage (TNM stage III+IV, OR=0.32, 95% CI: 0.19-0.54), tumor differentiation (poor differentiation, OR=0.56, 95% CI: 0.37-0.83), and lymph node metastasis (N1, 3.15, 95% CI: 1.56-6.36) in patients with PDAC. Our meta-analysis results suggest that CD133 is an efficient prognostic factor in PDAC. Overexpression of CD133 was significantly associated with clinical TNM stage, tumor differentiation and lymph node metastasis.
authors.affiliation: Department of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University Shanghai 200092, China.
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Oncology, Baoshan People Hospital Yunan, China.
authors.forename: Haojie
authors.initials: H
authors.lastname: Zhao
authors.affiliation: Department of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University Shanghai 200092, China.
authors.forename: Jianchun
authors.initials: J
authors.lastname: Gu
authors.affiliation: Department of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University Shanghai 200092, China.
authors.forename: Leizhen
authors.initials: L
authors.lastname: Zheng
mesh_terms: D000071916:AC133 Antigen; D015703:Antigens, CD / Q000032:analysis / Q000096:biosynthesis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D021441:Carcinoma, Pancreatic Ductal / Q000401:mortality / Q000473:pathology*; D006023:Glycoproteins / Q000032:analysis / Q000096:biosynthesis*; D006801:Humans; D014411:Neoplastic Stem Cells / Q000473:pathology*; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology*; D010455:Peptides / Q000032:analysis; D011379:Prognosis
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides
keywords: CD133; Pancreatic neoplasms; meta analysis